TITLE

Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial

AUTHOR(S)
Tanaka, Kumiko; Saisho, Yoshifumi; Manesso, Erica; Tanaka, Masami; Meguro, Shu; Irie, Junichiro; Sugiura, Hiroaki; Kawai, Toshihide; Jinzaki, Masahiro; Cobelli, Claudio; Itoh, Hiroshi
PUB. DATE
October 2015
SOURCE
Clinical Drug Investigation;Oct2015, Vol. 35 Issue 10, p675
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming one of the major therapeutic options for the treatment of type 2 diabetes mellitus (T2DM). This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta cell function, fat distribution and pancreas volume compared with metformin in Japanese overweight/obese patients with T2DM. Methods: A subpopulation of the Keio study for Initial treatment of type 2 Diabetes with Liraglutide versus Metformin (KIND-LM) study participants ( n = 20, 10 in oral metformin group and 10 in subcutaneous liraglutide group) who were enrolled at Keio University Hospital and underwent frequently sampled mixed meal tolerance test (MTT) and abdominal computed tomography (CT) at weeks 0 and 24 were included in this analysis. The patients were treated with either metformin or liraglutide throughout the 24-week study period. Results: Changes in glycemic parameters such as glycated hemoglobulin (HbA1c), glycated albumin and 1,5-anhydroglucitol at week 24 were comparable between the groups. An oral minimal model based on MTT revealed that static-phase beta cell responsiveness ( Φ) and static-phase disposition index were significantly increased at week 24 in the liraglutide group but not in the metformin group. There was no significant change in fat distribution as well as body weight at week 24 in either group. Serum amylase and lipase levels modestly but significantly increased in the liraglutide group during the study; however, there was no incidence of pancreatitis and pancreas volume was not changed in the liraglutide group. Conclusion: Liraglutide monotherapy for 24 weeks improved beta cell responsiveness with no change in either body weight or fat distribution. Further investigation is needed to clarify the mechanism by which liraglutide increases serum pancreatic enzymes. Trial Registration: The University Hospital Medical Information Network (UMIN) Clinical Trials Registry (); UMIN000004243.
ACCESSION #
109575290

 

Related Articles

  • Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. BUNCK, MATHIJS C.; CORNÉR, ANJA; ELIASSON, BJORN; HEINE, ROBERT J.; SHAGINIAN, RIMMA M.; TASKINEN, MARJA-RIITTA; SMITH, ULF; YKI-JÄRVINEN, HANNELE; DIAMANT, MICHAELA // Diabetes Care;Sep2011, Vol. 34 Issue 9, p2041 

    OBJECTIVE--We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after...

  • Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis. Gu, Shuyan; Shi, Jihao; Tang, Zhiliu; Sawhney, Monika; Hu, Huimei; Shi, Lizheng; Fonseca, Vivian; Dong, Hengjin // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Metformin is the first-line oral hypoglycemic agent for type 2 diabetes mellitus recommended by international guidelines. However, little information exists comparing it with acarbose which is also commonly used in China. This study expanded knowledge by combining direct and...

  • Preserving beta-cell function in DM2.  // Neurology Alert;Aug2009 Clinical Briefs in, Vol. 14 Issue 8, p15 

    The article provides a comparison on the one-year treatment of patients suffering from metformin-treated type 2 diabetes with exenatide and treatment with insulin glargine to improve beta-cell function. It references a study by MC Bunck and others, published in the 2009 issue of "Diabetes Care."...

  • Combination sitagliptin/metformin improved beta cell function, HbA1c. Barzilai, Nir; Grassia, Tara; Kalvaitis, Katie // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p7 

    The article discusses a study which examined the effect of initial combination therapy with sitagliptin and metformin. Patients were randomly assigned to one of five treatment groups. Results showed that the therapy improved blood glucose levels and markers of beta cell function in patients with...

  • Goals of Treatment for Type 2 Diabetes. Marchetti, Piero; Lupi, Roberto; Del Guerra, Silvia; Bugliani, Marco; D'Aleo, Valentina; Occhipinti, Margherita; Boggi, Ugo; Marselli, Lorella; Masini, Matilde // Diabetes Care;Nov2009 Supplement, Vol. 32, pS178 

    The article discusses the possibility to treat type 2 diabetes by preserving β-cells and preventing the deterioration of glucose control. The findings of several studies on β-cell function among subjects with normal and impaired glucose tolerance are tackled. Also tackled are the effects...

  • Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus. Signorovitch, James E.; Wu, Eric Q.; Swallow, Elyse; Kantor, Evan; Fan, Liangyi; Gruenberger, Jean-Bernard // Clinical Drug Investigation;2011, Vol. 31 Issue 9, p665 

    Background and Objective: Vildagliptin and sitagliptin are oral dipeptidyl peptidase 4 inhibitors approved in Japan for the treatment of type 2 diabetes mellitus when adequate glycaemic control is not achieved with diet, exercise or sulphonylureas. The aim of this study was to compare 12-week...

  • Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy. Barnett, Anthony; Charbonnel, Bernard; Li, Jia; Donovan, Mark; Fleming, Douglas; Iqbal, Nayyar // Clinical Drug Investigation;Oct2013, Vol. 33 Issue 10, p707 

    Background: Achievement of glycemic control is an important objective in the management of type 2 diabetes mellitus (T2DM). Objective: The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase-4 inhibitor saxagliptin versus placebo as add-on therapy in...

  • Effect of Folic Acid Supplementation on Indices of Glycemic Control, Insulin Resistance and Lipid Profile in Patients With Type 2 Diabetes Mellitus. Aghamohammadi khiavi, V.; Pourghassem Gargari, B.; Aliasgharzadeh, A. // Iranian Journal of Endocrinology & Metabolism;Nov2011, Vol. 13 Issue 4, p424 

    Introduction: This study was performed to determine the effects of supplementation of folate on indices of glycemic control, insulin resistance and lipid profile in in men with type 2 diabetes, under metformin (at least 1500mg daily) treatment. Materials and Methods: This was a double-blind...

  • Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Guzmán, Juan Rosas; Lyra, Ruy; Aguilar-Salinas, Carlos A.; Cavalcanti, Saulo; Escaño, Felix; Tambasia, Marcos; Duarte, Elizabeth // Pan American Journal of Public Health;Dec2010, Vol. 28 Issue 6, p463 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics